Yayın:
Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies

Sadeleştirilmiş öğe sayfası
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorScott J. Rodig
dc.contributor.authorВ Я Мельниченко
dc.contributor.authorCatherine Thiéblemont
dc.contributor.authorKrimo Bouabdallah
dc.contributor.authorGayane Tumyan
dc.contributor.authorMuhi̇t Özcan
dc.contributor.authorSergio Portiño
dc.contributor.authorLaura Maria Fogliatto
dc.contributor.authorDolores Caballero
dc.contributor.authorJan Walewski
dc.contributor.authorZafer Gülbaş
dc.contributor.authorVincent Ribrag
dc.contributor.authorBeth Christian
dc.contributor.authorGuilherme Fleury Perini
dc.contributor.authorGilles Salles
dc.contributor.authorJakub Svoboda
dc.contributor.authorJasmine Zain
dc.contributor.authorSanjay S. Patel
dc.contributor.authorPei-Hsuan Chen
dc.contributor.authorAzra H. Ligon
dc.contributor.authorJing Ouyang
dc.contributor.authorDonna Neuberg
dc.contributor.authorRobert Redd
dc.contributor.authorArkendu Chatterjee
dc.contributor.authorRobert Orlowski
dc.contributor.authorArun Balakumaran
dc.contributor.authorMargaret A. Shipp
dc.contributor.authorPier Luigi Zinzani
dc.contributor.orcid0000-0001-6098-1603
dc.contributor.orcid0000-0003-1761-9769
dc.contributor.orcid0000-0002-6728-6264
dc.contributor.orcid0000-0002-9941-2448
dc.contributor.orcid0000-0002-4425-7823
dc.contributor.orcid0000-0002-5771-4413
dc.contributor.orcid0000-0002-1326-1918
dc.contributor.orcid0000-0002-2996-620X
dc.contributor.orcid0000-0002-0610-7971
dc.contributor.orcid0000-0003-4247-2674
dc.contributor.orcid0000-0002-4709-0627
dc.contributor.orcid0000-0002-5221-353X
dc.contributor.orcid0000-0001-7235-1334
dc.contributor.orcid0000-0002-9541-8666
dc.contributor.orcid0000-0002-6359-7065
dc.contributor.orcid0009-0009-0753-1019
dc.contributor.orcid0000-0001-7621-453X
dc.contributor.orcid0000-0001-7585-2441
dc.contributor.orcid0000-0001-5902-7070
dc.contributor.orcid0000-0003-2566-3145
dc.contributor.orcid0000-0002-1329-5288
dc.contributor.orcid0000-0001-7884-6928
dc.contributor.orcid0000-0002-8037-9932
dc.contributor.orcid0000-0002-3949-6897
dc.contributor.orcid0000-0002-2112-2651
dc.date.accessioned2025-11-13T09:45:21Z
dc.date.issued2018-11-29
dc.identifier.doihttps://doi.org/10.1182/blood-2018-99-110220
dc.identifier.endpage228
dc.identifier.issn0006-4971
dc.identifier.issueSupplement 1
dc.identifier.openalexW2903843213
dc.identifier.startpage228
dc.identifier.urihttps://hdl.handle.net/11421/2093
dc.identifier.urihttps://doi.org/10.1182/blood-2018-99-110220
dc.identifier.volume132
dc.language.isoen
dc.relation.ispartofBlood
dc.rightsrestrictedAccess
dc.subjectPembrolizumab
dc.subjectMedicine
dc.subjectRefractory (planetary science)
dc.subjectInternal medicine
dc.subjectOncology
dc.subjectClinical endpoint
dc.subjectLymphoma
dc.subjectPhases of clinical research
dc.subjectSurgery
dc.subjectClinical trial
dc.subjectImmunotherapy
dc.subjectCancer
dc.titlePembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5058571002

Dosyalar

Koleksiyonlar

Publications